|
1) Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-45
|
|
|
|
2) 近藤有好. 薬剤による肺障害. 結核. 1999; 74: 33-41
|
|
|
|
|
3) Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. JMAJ. 2007; 50: 405-11
|
|
|
|
|
|
4) 工藤翔二. ミニ特集 薬剤性肺障害｢日本人にとっての薬剤性肺障害｣. 日本胸部臨床. 2006; 65: 963-70
|
|
|
|
|
|
5) Sakai F, Noma S, Kurihara Y, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Modern Rheumatology. 2005; 15: 173-9
|
|
|
|
|
6) http://www.chugai-pharm.co.jp/hc/di;jsessionid＝00M2AX3SECVQACSSUIHSFEQ (2008. 10現在)
|
|
|
|
|
|
7) Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest. 1993; 103: 1808-12
|
|
|
|
|
|
8) Sordella R, Bell DW, Daniel AH, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305: 1163-7
|
|
|
|
|
|
9) Lynch TJ, Bell DW, Sordella R, et al. Activating Mutations in the EGFR Underlying Responsive-ness of NSCLC to gefitinib. N Engl J Med. 2004; 350: 2129-39
|
|
|
|
|
|
10) Azuma A, Hagiwara K, Kudoh S. Letter; Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese. Am J Respir Crit Care Med. 2008; 177: 1397-8
|
|
|
|
|